BARDA previously spent more than $ 160 million on a previous safety study of the treatment.
Meanwhile an important investment in vaccines: Novavax was allocated $ 1.6 billion by the federal government to conduct a late-stage trial of its vaccine candidate, ramp up production, and potentially deliver 100 million doses by the end of this year.
The federal award is the largest to be awarded to a vaccine candidate through BARDA and will be conducted under Operation Warp Speed, which aims to market the candidate vaccines, including those from Johnson & Johnson, Moderna and AstraZeneca. Novavax’s vaccine candidate is the sixth to receive significant federal funding, and if it turns out to be effective, HHS said the doses would be available to Americans for free.
The Novavax candidate has not yet overcome the hurdle for security research, but a Phase I / II investigation was launched in Australia in May. The company said results are expected at the end of this month.
The Pentagon previously awarded $ 70 million to Novavax to manufacture components of its vaccine in the US and to administer 10 million doses for use in late-stage clinical work or if the vaccine is authorized for emergency use.
What’s next: Clinical trials are expected to begin this month for several other coronavirus candidates, including those of Moderna and Pfizer. The tests must provide insight into whether the vaccines are working.
Each trial is expected to include 30,000 participants and is partially conducted in the US. Moderna has received over $ 500 million in government funding, while Pfizer has not received any money. Both companies have said they work with Operation Warp Speed.